Edition:
United Kingdom

Pharmaceuticals

Page 1

Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria

Friday, 15 Dec 2017

Dec 15 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS ANNOUNCES STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY.ARATANA THERAPEUTICS - RECEIVED TOP-LINE PIVOTAL FIELD EFFECTIVENESS STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS - PARTNER RESPONSIBLE FOR AT-016 SHARED RESULTS OF PIVOTAL STUDY, WHICH DID NOT ACHIEVE PROTOCOL-DEFINED EFFICACY SUCCESS CRITERIA.ARATANA THERAPEUTICS INC - AS PART OF CO'S EXCLUSIVE COMMERCIAL LICENSE FOR DOGS WITH OSTEOARTHRITIS IN U.S., CO FUNDED CLINICAL STUDY & OTHER WORK.ARATANA THERAPEUTICS - CO ANTICIPATES AFTER PARTNER EVALUATED STUDY RESULTS, PARTIES TO DETERMINE IF COLLABORATION TO BRING THERAPEUTIC TO MARKET TO CONTINUE.

CO.DON CEO Resigns From Year-End 2017

Friday, 15 Dec 2017

Dec 15 (Reuters) - CO DON AG ::CEO RESIGNS FROM YEAR-END 2017.DIRK HESSEL RESIGNS FROM HIS POSITION AS MEMBER AND CHAIRMAN OF MANAGEMENT BOARD WITH EFFECT FROM DEC. 31.

Zhejiang Shapuaisi Pharma's Share Trade To Resume After Responding To Regulator's Queries

Friday, 15 Dec 2017

Dec 15 (Reuters) - Zhejiang Shapuaisi Pharmaceutical Co Ltd <603168.SS>::SAYS SHARE TRADE TO RESUME ON DEC 18 AFTER RESPONDING TO SHANGHAI EXCHANGE AND REGULATOR'S QUERIES REGARDING ITS EYE DROP PRODUCTS.SAYS IT HAS NOT HALTED PRODUCTION, THOUGH SALES OF ITS EYE PRODUCTS WILL BE AFFECTED.

IntelGenx Receives Health Canada Clearance To Begin Phase 2a Study With Montelukast Versafilm

Friday, 15 Dec 2017

Dec 15 (Reuters) - IntelGenx Technologies Corp ::INTELGENX RECEIVES HEALTH CANADA CLEARANCE TO BEGIN PHASE 2A STUDY WITH MONTELUKAST VERSAFILM(TM) IN MILD TO MODERATE ALZHEIMER'S DISEASE.INTELGENX TECHNOLOGIES SAYS PHASE 2A PROOF OF CONCEPT CLINICAL STUDY WILL START SCREENING AD PATIENTS IN Q1 2018.

EU Medicines Agency Recommendations For December 2017 ‍​

Friday, 15 Dec 2017

Dec 15 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDATIONS FOR DECEMBER 2017 ‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF NOVO NORDISK'S ONCE-WEEKLY DIABETES DRUG SEMAGLUTIDE‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF KYOWA HAKKO KIRIN DRUG FOR GENETIC BLOOD DISORDER XLH BUROSUMAB.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TIGENIX'S STEM CELLS TREATMENT FOR PERIANAL FISTULAS ALOFISEL.

Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

Friday, 15 Dec 2017

Dec 15 (Reuters) - TIGENIX NV ::REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE.‍FIRST ALLOGENEIC STEM CELL THERAPY TO RECEIVE POSITIVE CHMP OPINION IN EUROPE​.‍CX601 OFFERS POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WHO DO NOT RESPOND TO CURRENT AVAILABLE THERAPIES AND ARE SUBJECT TO NUMEROUS INVASIVE SURGERIES​.‍RECEIPT OF MA WILL TRIGGER A MILESTONE PAYMENT FROM TAKEDA TO TIGENIX OF EUR 15 MILLION​.

Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

Friday, 15 Dec 2017

Dec 15 (Reuters) - PHARMA MAR SA ::THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA.AFTER OPINION OF CHMP, EUROPEAN COMMISSION TO ISSUE FINAL DECISION, EXPECTED IN MARCH OR APRIL, 2018.

Sanofi India Appoints Rajaram Narayanan As MD‍​

Friday, 15 Dec 2017

Dec 15 (Reuters) - Sanofi India Ltd ::SAYS SHAILESH AYYANGAR STEPS DOWN AS MD‍​.SAYS RAJARAM NARAYANAN APPOINTED AS MD‍​.

Ajanta Pharma's Vice-Chairman​ Purushottam B. Agrawal Resigns

Friday, 15 Dec 2017

Dec 15 (Reuters) - Ajanta Pharma Ltd ::SAYS ‍ PURUSHOTTAM B. AGRAWAL RESIGNS AS VICE-CHAIRMAN​.

R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I

Friday, 15 Dec 2017

Dec 15 (Reuters) - Shionogi & Co Ltd <4507.T> ::Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook stable -R&I.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary